We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

QuidelOrtho Demonstrates Automated, Sample-To-Result, Multiplex RT-PCR Testing Platform at Medlab Middle East 2023

By LabMedica International staff writers
Posted on 08 Feb 2023
Image: QuidelOrtho is demonstrating how to improve workflow and respond more flexibly and quickly to patient needs (Photo courtesy of QuidelOrtho)
Image: QuidelOrtho is demonstrating how to improve workflow and respond more flexibly and quickly to patient needs (Photo courtesy of QuidelOrtho)

At Medlab Middle East 2023, QuidelOrtho Corporation (San Diego, CA, USA) is showcasing for the first time the benefits of the combined organization’s consolidated portfolio of world-class technologies and platforms, through expanded access to clinical chemistry, immunoassay, molecular diagnostics, immunohematology, donor screening, and point-of-care diagnostics offerings.

At the QuidelOrtho booth, the focus is on the Savanna automated, sample-to-result, multiplex RT-PCR testing platform that performs real-time Polymerization Chain Reaction (PCR) tests by using the Savanna instrument and Savanna assay cartridges. This evolutionary multiplex molecular platform enables professional customers to analyze up to 12 pathogens or targets, plus controls, from a single assay run in less than 30 minutes. After inserting the assay cartridge, the instrument performs sample and reagent preparation, nucleic acid extraction and amplification, real-time detection of RNA or DNA target sequence, and qualitative or quantitative result interpretation from a variety of sample types. The Savanna system is intended to aid in the diagnosis of the related diseases.

QuidelOrtho is also demonstrating the Savanna RVP4 Assay (Respiratory Viral Panel-4), a rapid, multiplexed nucleic acid test intended for use with the Savanna instrument for the simultaneous qualitative detection and differentiation of influenza A (Flu A), influenza B (Flu B), respiratory syncytial virus (RSV), and SARS-CoV-2 RNA isolated from human nasal or nasopharyngeal swabs in media obtained from patients with signs and symptoms of respiratory tract infection. The in vitro diagnostic test is intended to aid in the differential diagnosis of infections with these viruses. The Savanna RVP4 Assay comes in a fully integrated cartridge that is stable at room temperature.

Related Links:
QuidelOrtho Corporation 

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Portable POCT Blood Gas Analyzer
BD100
Urine Analyzer
respons® UDS100

Channels

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image Credit: Adobe Stock

Companion Diagnostics Expand HER2 Testing in Metastatic Gastroesophageal Cancer

Gastroesophageal adenocarcinoma comprises a group of aggressive cancers that are often diagnosed at an advanced stage and carry poor prognoses. Gastric and esophageal cancers rank among the leading causes... Read more